9 Meters Biopharma Inc (NMTRQ)

[Vance]

$5 Price Target Article!

https://m.benzinga.com/article/17140372

Shares of 9 Meters Biopharma Inc (NASDAQ: NMTR) were ripping higher following a bullish initiation by Brookline Capital Markets.

The 9 Meters Analyst: Analyst Sally Yanchus initiated coverage of 9 Meters shares with a Buy rating and $5 price target, suggesting about 800% upside potential from current levels.



?


The 9 Meters Takeaways: 9 Meters focuses on two gastrointestinal disorders: celiac disease and short bowel syndromes. The GI conditions represent significant unmet medical needs, Yanchus said in a note.

The company's lead product candidate Larazotide is in Phase 3 studies, and a top-line readout from the trial is expected in the second half of 2021, Yanchus said.

A second asset, a long-acting GLP-1 agonist for short bowel syndrome, entered Phase 1b/2a trials in June, with the Phase 3 studies likely to commence in the second half of 2021, according to Brookline.